CN114786647B - 口服药学立即释放组合物和用于重量减轻的治疗方法 - Google Patents

口服药学立即释放组合物和用于重量减轻的治疗方法 Download PDF

Info

Publication number
CN114786647B
CN114786647B CN202080066539.0A CN202080066539A CN114786647B CN 114786647 B CN114786647 B CN 114786647B CN 202080066539 A CN202080066539 A CN 202080066539A CN 114786647 B CN114786647 B CN 114786647B
Authority
CN
China
Prior art keywords
denatonium
acetate
salt
formulation
adults
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080066539.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114786647A (zh
Inventor
Z·郑
T-L·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adawac Treatment Co
Original Assignee
Adawac Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adawac Treatment Co filed Critical Adawac Treatment Co
Priority to CN202510488506.XA priority Critical patent/CN120420287A/zh
Publication of CN114786647A publication Critical patent/CN114786647A/zh
Application granted granted Critical
Publication of CN114786647B publication Critical patent/CN114786647B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202080066539.0A 2019-09-25 2020-09-24 口服药学立即释放组合物和用于重量减轻的治疗方法 Active CN114786647B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510488506.XA CN120420287A (zh) 2019-09-25 2020-09-24 口服药学立即释放组合物和用于重量减轻的治疗方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905943P 2019-09-25 2019-09-25
US62/905,943 2019-09-25
PCT/US2020/052588 WO2021062061A1 (en) 2019-09-25 2020-09-24 Oral pharmaceutical immediate release composition and method of treatment for weight loss

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510488506.XA Division CN120420287A (zh) 2019-09-25 2020-09-24 口服药学立即释放组合物和用于重量减轻的治疗方法

Publications (2)

Publication Number Publication Date
CN114786647A CN114786647A (zh) 2022-07-22
CN114786647B true CN114786647B (zh) 2025-05-06

Family

ID=75167128

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080066539.0A Active CN114786647B (zh) 2019-09-25 2020-09-24 口服药学立即释放组合物和用于重量减轻的治疗方法
CN202510488506.XA Pending CN120420287A (zh) 2019-09-25 2020-09-24 口服药学立即释放组合物和用于重量减轻的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510488506.XA Pending CN120420287A (zh) 2019-09-25 2020-09-24 口服药学立即释放组合物和用于重量减轻的治疗方法

Country Status (8)

Country Link
US (1) US20220280457A1 (https=)
EP (1) EP4034082A4 (https=)
JP (1) JP7680762B2 (https=)
KR (1) KR20220106960A (https=)
CN (2) CN114786647B (https=)
AU (1) AU2020354634A1 (https=)
CA (1) CA3151431A1 (https=)
WO (1) WO2021062061A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3215858A1 (en) * 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound
WO2023064480A1 (en) 2021-10-14 2023-04-20 Aardvark Therapeutics Inc. Monohydrate salt of denatonium acetate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
KR20040063616A (ko) * 2003-01-08 2004-07-14 김원호 다이어트 식품용 조제
EP1991054A4 (en) * 2005-11-10 2012-04-25 Univ Minnesota SYSTEMIC PLANT STRENGTHENER
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
EP2582367A4 (en) * 2010-06-17 2013-11-27 California Inst Of Techn METHOD AND SYSTEM FOR MODULATING HORMONES AND RELATED METHODS, ACTIVE SUBSTANCES AND COMPOSITIONS
EP2661266B1 (en) * 2011-01-07 2020-09-16 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
EP3138900A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Detergent compositions and wrapping films therefor having at least two different aversive agents and methods related thereto
EP3138897A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Films at least 80 microns thick comprising aversive agents, unit dose detergent articles wrapped therein, uses and methods related thereto
EP3138898A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Water-soluble detergent articles wrapped in a film with an aversive agent mainly in the flanges or skirt thereof
US10835505B2 (en) 2018-06-11 2020-11-17 Aardvark Therapeutics, Inc. Oral pharmaceutical formulation for weight loss, diabetes and related disorders
US12201593B2 (en) 2018-07-02 2025-01-21 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for asthma
WO2020014494A1 (en) * 2018-07-11 2020-01-16 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension
EP4081201A4 (en) * 2019-12-24 2024-01-10 Aardvark Therapeutics Inc. Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
First-in-Human Evaluation of Oral Denatonium Acetate (ARD-101), a Potential Bitter Taste Receptor Agonist: A Randomized, Double-Blind, Placebo- Controlled Phase 1 Trial in Healthy Adults;Andreas G Niethammer等;《Clin Pharmacol Drug Dev》;第11卷(第8期);第997-1006页 *

Also Published As

Publication number Publication date
AU2020354634A1 (en) 2022-04-14
CA3151431A1 (en) 2021-04-01
EP4034082A4 (en) 2023-07-05
WO2021062061A1 (en) 2021-04-01
JP2022549833A (ja) 2022-11-29
CN120420287A (zh) 2025-08-05
US20220280457A1 (en) 2022-09-08
EP4034082A1 (en) 2022-08-03
KR20220106960A (ko) 2022-08-01
CN114786647A (zh) 2022-07-22
JP7680762B2 (ja) 2025-05-21

Similar Documents

Publication Publication Date Title
US10835505B2 (en) Oral pharmaceutical formulation for weight loss, diabetes and related disorders
CN103025317B (zh) 钠布啡类制剂及其用途
EP2900230B1 (en) Compounds for the treatment of obesity and methods of use thereof
JP2005508865A (ja) アポモルフィン、６ａＲ−（−）−Ｎ−プロピル−ノルアポモルフィンおよびそれらの誘導体、並びにそれらのプロドラッグを効率的に投与するための薬学的処方剤
WO2008122190A1 (en) The composition comprising l-carnitine or derivatives thereof and its use
EP1750677A1 (en) Oral therapeutic compound delivery system
US20140112983A1 (en) Nitrite compositions and uses thereof
WO2022098879A1 (en) Sustained release solid dosage forms for modulating the colonic microbiome
CN1141937C (zh) 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物
CN114786647B (zh) 口服药学立即释放组合物和用于重量减轻的治疗方法
JP2007509146A (ja) レボドーパの持続効果のための組成物及び投与形
US20250032520A1 (en) Oral cannabinoid compositions and methods for treating neurological diseases and disorders
US20150110865A1 (en) Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment
KR20160012706A (ko) 서방성 제제
CN111867578A (zh) 包含帕马考昔及普瑞巴林的用于治疗疼痛的药剂学组合物
US20220087960A1 (en) Oral Pharmaceutical Immediate Release Composition
CN100404025C (zh) 含有盐酸曲马多和对乙酰氨基酚的口崩片及其制备方法
CN113813250A (zh) 含氯胺酮的药物组合物及其制备方法和应用
JP2000264839A (ja) 結腸領域で高まった疼痛感応性と関連する機能障害及び／又は下行腸管の疾患の治療及び／又は予防のための医薬調剤並びにその製造法
CN114786711A (zh) 预防或治疗肠易激综合征的药物组合
US12539286B2 (en) Compositions of β-aminoisobutyric acid and methods for use thereof
RU2264814C2 (ru) Антигистаминная фармацевтическая композиция
JPH02142732A (ja) 肥満並びに肥満に関連する各種疾患の治療剤
CN115721636A (zh) 一种双多巴缓释组合物及其制备方法
CN118871096A (zh) 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant